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Background. The American Association for the Study of Liver Diseases (AASLD) recommends semi-annual
hepatocellular carcinoma (HCC) screening using ultrasound (US) in persons with chronic hepatitis B (CHB)
virus infection at high risk for HCC such as Asian males aged ]40 years and Asian females aged ]50 years.
Objective. To analyse the cost-effectiveness of 2 HCC screening methods in the Alaska Native (AN) health
system: US-alone, or screening by alpha-fetoprotein (AFP) initially and switching to US for subsequent
screenings if AFP 10 ng/mL (AFP0US).
Design. A spreadsheet-based model was developed for accounting the costs of 2 hypothetical HCC screening
methods. We used epidemiologic data from a cohort of 839 AN persons with CHB who were offered
HCC screening by AFP/US semi-annually during 19832012. We assumed that compared with AFP0US,
US-alone identifies 33% more tumours at an early stage (defined as a single tumour 55 cm or 53 tumours
53 cm in diameter). Years of life gained (YLG) attributed to screening was estimated by comparing
additional years of survival among persons with early- compared with late-stage tumours. Screening costs
were calculated using Medicare reimbursement rates in 2012. Future screening costs and YLG were projected
over a 30-year time horizon using a 3% discount rate.
Results. The total cost of screening for the cohort by AFP0US would have been approximately $357,000
($36,000/early-stage tumour detected) compared to $814,000 ($59,000/early-stage tumour detected) by
US-alone. The AFP0US method would have yielded an additional 27.8 YLG ($13,000/YLG) compared with
38.9 YLG ($21,000/YLG) for US-alone. Screening by US-alone would incur an additional $114,000 per extra
early-tumour detected compared with AFP0US and $41,000 per extra YLG.
Conclusions. Although US-alone HCC screening might have yielded more YLG than AFP0US, the reduced
costs of the AFP0US method could expand access to HCC screening in resource constrained settings.
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T
he World Health Organization estimates that 360
million persons live with chronic hepatitis B virus
infection (CHB) worldwide (1). Persons with CHB
are at increased risk for developing hepatocellular carci-
noma (HCC) (2). The American Association for the
Study of Liver Diseases (AASLD) guidelines recommend
HCC screening when the risk exceeds 0.2% year within
a population group, such as among Asian males aged
40 years and Asian females aged 50 years (3). The
optimal method for HCC screening remains debatable (4).

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AASLD guidelines for managing CHB recommend
screening of persons at high risk for HCC by ultrasound
(US) every 612 months, but list serum alpha-fetoprotein
(AFP) as an acceptable alternative in areas of the United
States where US is not readily available (5). Conversely,
separate AASLD guidelines for managing HCC state
that AFP lacks sufficient sensitivity/specificity to serve as
a useful screening test and, therefore, recommend screen-
ing every 6 months by US alone (3).
Alaska Native (AN) persons with CHB have an annual
risk of 0.26% for developing HCC and might benefit
from semi-annual HCC screening (3,6). Alaska is a large
sparsely populated state, and a substantial proportion
of AN people live in small villages that are inaccessible
by road. In villages without an US facility, the costs
associated with transporting persons by air to an US-
capable regional health centre are an important barrier to
HCC screening by US alone. For that reason, the Alaska
Native Tribal Health System has screened all persons with
CHB for HCC by semi-annual serum AFP measurements;
only persons with an elevated AFP and persons with a
family history of HCC or cirrhosis were referred for US.
Between 1982 and 1987, more than 53,000 AN persons
were screened for CHB in a mass vaccination campaign
(7); 1,535 persons tested positive for hepatitis B surface
antigen during and after the campaign. All persons testing
positive for hepatitis B surface antigen were offered semi-
annual screening for HCC through the Alaska Native
Tribal Health System. In total, 1,375 AN persons with
CHB provided consent to enroll in a prospective cohort
study that followed participants from January 1983 to
December 2012. This prospective study was approved by
the Institutional Review Boards of the Alaska Native
Tribal Health Consortium and the Centres for Disease
Control and Prevention. For this present study, we used
data from the prospectively studied cohort of AN persons
with CHB to compare the cost-effectiveness of HCC
screening by 2 methods: screening by US semi-annually
(US-alone method) versus semi-annual screening by AFP
alone and switching to US alone if an AFP 10 ng/m
was detected (AFP0US method). Our analysis can guide
public health officials on choosing the optimal HCC
screening method for persons with CHB living in resource
constrained settings where US is not available, and the
cost of transportation to an US-equipped facility can be a
barrier.
Methods
We built a spreadsheet-based model to compare the
cost-effectiveness of HCC screening by US-alone and
AFP0US methods. For the US-alone method, we
assumed patients would have received an US at every
screening opportunity. For the AFP0US method, we
assumed that all persons would have been screened by AFP
initially and switched to US for all subsequent screening
opportunities if AFP 10 ng/mL on at least 1 measure-
ment. Based on AASLD guidelines criteria (3), we
assumed that HCC screening in the prospectively followed
cohort of AN persons with CHB began for all males
and females once they attained ages ]40 and ]50 years,
respectively. Under both screening methods, we assumed
that HCC screening continued until patient death or the
end of the study period (December 31, 2012).
Epidemiologic data
For this cost-effectiveness analysis, we used data from AN
patients with CHB who participated in the prospective
cohort study during 19832012 (see Appendix Table I
for cohort participants’ demographic and clinical char-
acteristics). We reviewed the medical records for cohort
participants to determine the: (a) dates and results of all
AFP measurements, (b) date of HCC diagnosis, and
(c) date of death. For persons who developed HCC, the
dates and results of all liver imaging studies were obtained
from the medical records. Additionally, we cross-referenced
the names of persons in the study cohort with the Alaska
Native Tumour Registry, a participant of the National
Cancer Institute Surveillance, Epidemiology, and End
Results Program, to identify persons with HCC (8).
Cohort participants who died or developed HCC B6
months after cohort entry were excluded from our
analysis because they likely would not have benefited
from either screening method. In total, 564 males attained
age ]40 years and 275 females attained age ]50 years
during 19832012 (the age/sex target group for HCC
screening) and their data provided epidemiologic input for
our model (Table I). Among cohort participants included
in our analysis, 21 were diagnosed with HCC ]6 months
after cohort entry.
Tumour stage classification
The HCC tumour size was determined by either US or
computed tomography (CT). If the number of tumours or
tumour sizes were discrepant between ultrasound and CT
for the same patient, we used the CT imaging results. We
categorised patients with HCC as having an early-stage
tumour as defined by the Milan criteria as follows: single
tumour 55 cm in diameter or 53 tumours each 53 cm
in diameter, and no vascular or lymph node invasion (9).
Tumours not meeting Milan criteria were categorised
as late-stage. To be conservative and not overestimate
potential benefits of HCC screening, we also categorised
as late-stage those tumours of unknown size (for patients
who declined additional evaluation).
Estimating the number of early-stage tumours
identified by each screening method
Neither the AFP0US method nor the US-alone method
was used in practice in the prospectively followed cohort.
Therefore, we had to make assumptions to estimate the
number of HCC tumours that would have been identified
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at an early stage by the 2 hypothetical screening methods
(AFP0US and US-alone) based on the results of the
actual HCC screening method used in the prospectively
followed cohort during 19832012. For the actual HCC
screening method, all AN patients with CHB were
offered screening by AFP every 6 months regardless of
age or risk factors for developing HCC and only those
patients at high risk for HCC or with an elevated AFP
were referred for US. Because the hypothetical AFP0US
method closely resembles the actual screening method,
we assumed the AFP0US method would have identified
the same number of early-stage tumours as the actual
screening method (Tables I and II).
In order to determine the number of early-stage
tumours detected by the hypothetical US-alone method,
we assumed that approximately 33% of the late-stage
tumours identified by the actual screening method in the
cohort would instead have been identified at an early stage
by the US-alone method. This assumption was based
on a previous study demonstrating that the sensitivity of
AFP 10.9 ng/mL for detecting early-stage HCC was
66%, and on a meta-analysis which reported a pooled
sensitivity for ultrasound of 63% for detecting an early-
stage HCC and 94% for detecting any tumour before
becoming clinically apparent (10,11). Although the sensi-
tivity of US to detect HCC tumours can be lower in certain
circumstances, such as in persons with cirrhosis, we opted
to use the best-case scenario US sensitivity of 94% when
comparing with AFP because guidelines presume that US
is superior to AFP for HCC screening (3,5,12).
Estimating survival by tumour stage
For both hypothetical screening approaches, we calculated
the additional years of life gained (YLG) in the cohort
of 839 persons with CHB compared with no screening. We
assumed that the median (mean) years of survival among
persons with late-stage HCC tumours represented survival
with no screening. We further assumed that the additional
YLG at median (mean) among persons with early-stage
tumours were the result of screening (Table I). All persons
within a tumour-stage category were assumed to have the
same median (mean) survival by either the AFP0US
approach or the US-alone approach (Table I); only the
number of persons within each tumour-stage category
differed between the 2 approaches (Table II). We calculated
the additional median YLG attributable to screening as
follows:
Additional YLG at median survival[(# early-
stage tumours)(survival in early-stage tumour)] 
[(# late-stage tumours)(survival in late-stage tumours)].
Table I. Epidemiologic data for a cost analysis from a prospec-
tively followed cohort of AN persons with chronic hepatitis B
virus infection, 19832012
Epidemiologic input Data
Number of cohort participantsa 839
Males (%) 564 (67%)
Number of cohort participants with HCC (%) 21 (2.5%)
Early-stage tumourb 10
Median (mean) years survival by tumour stage
Early stageb 3.1 (5.0)
Late stage 0.2 (0.8)
Total number of potential screening opportunitiesc 21,226
Total number of AFP measurements in cohortd 10,931
Median AFP measurements/person 11
% of total potential screening opportunities 51%
AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; US,
ultrasound.
aComprises males attaining age ]40 years and females attaining
age ]50 years during January 1, 1983 to December 31, 2012.
bSingle tumour 55 cm in diameter or 53 tumours 53 cm in
diameter. cAssumes persons received screening for HCC every
6 months. dAssumes persons received screening for HCC
on dates for which an AFP measurement was documented
(excluding AFP measurements occurring B4 months after a prior
measurement).
Table II. Base-case model assumptions for estimating the costs
for hepatocellular carcinoma screening
Model input Assumption
Number of screening tests performed by AFP0USa 10,931
Number of AFP measurements 9,378
Number of US screenings 1,553
Number of ultrasounds performed by US-alone
methodb
10,931
Tumours detected at an early stage by AFP0US
methodc
10
Tumours detected at an early stage by US-alone
method according to sizec,d
14
Direct costs per test
(Medicare reimbursement rates in 2012)
AFP $109.94
US $26.76
Roundtrip cost/patient to an US-equipped facilitye $200
% cohort members requiring transportation to US
facility
60%
AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; US,
ultrasound.
aAssumes patients received screening for HCC by serum AFP
measurements initially and switched to ultrasound for all
subsequent screenings if AFP 10 ng/mL. bAssumes patients
received screening for HCC by ultrasound on dates for which
AFP measurements are recorded. cSingle tumour 55 cm in
diameter or 53 tumours 53 cm in diameter. dAssumes 33% (4)
of tumours identified at a late stage by the AFP0US method
were identified by the US-alone method at an early stage. eFor
patients living in rural Alaska areas without ready access to US.
Cost of two methods to HCC screening
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Total number of screening tests performed
We estimated the number of screening tests that would
have been performed in the 839 cohort participants meet-
ing age/sex criteria for HCC screening during the 30-year
time horizon of our study by assuming that screening
occurred only on dates of when documented AFP tests
were actually performed. We further assumed that it would
be unlikely that a person failing to have their blood drawn
would instead comply with a recommendation to obtain
an US. We thus assumed that the total number of
documented AFP measurements also represents the po-
tential US screening opportunities. We then determined
the total number of AFP and US tests that would have been
performed under the 2 hypothetical screening methods.
Assuming that all cohort members received a screening
test for HCC every 6 months, there were a total of
21,226 screening opportunities in the cohort during the
30-year time horizon (Table I). However, AFP measure-
ments were documented for only 10,931 (51.4%) screening
opportunities (median: 11 HCC screening tests/person).
By the AFP0US method, screening would have occurred
by measuring serum AFP at 9,378 opportunities and by
US at 1,553 opportunities among persons with at least 1
elevated serum AFP (Table II). By the US-alone method,
we assume that an US would have been performed at all
10,931 screening opportunities (Table II).
Cost analysis
We estimated direct costs of screening from the payer’s
perspective, the Alaska Native Health System. We used
2012 Medicare reimbursement rates in Alaska for AFP
and US ($26.76 and $109.94 per test, respectively) to
calculate the cost of screening at our institution (based on
personal communication, Alaska Native Medical Center).
For the 60% of patients living in communities without an
US facility, we estimated that air transportation to the
nearest regional health centre costs on average $200 per
person per round trip. We also compared the 2 screening
methods in terms of the cost/tumour detected by summing
the cost of all AFP and US measurements that would
have been performed in the cohort under each screening
method and dividing by the number of tumours detected
at an early stage in the cohort. We did not account for
treatment costs after early- or late-tumour detections
because we assumed that treatment costs will be similar
irrespective of the methods used to detect tumour.
Cost-effectiveness calculations
We evaluated the cost-effectiveness of the AFP0US and
US-alone approaches in terms of the cost/tumour detected
and the cost/YLG. The cost/tumour detected was calcu-
lated by summing the cost of all AFP and US measure-
ments that would have been performed in the cohort under
each screening approach and dividing by the number of
early-stage tumours detected in the cohort. The cost/YLG
was calculated by summing the cost of all AFP and US
measurements that would have been performed in the
cohort under each screening approach and dividing by the
total number of YLG under each approach, respectively.
The cost/YLG was calculated by using both the both
the mean and median estimates for YLG. Finally, to
account for differences in time between when screening
costs may occur and health benefits are obtained, we
discounted future costs and benefits (e.g. health outcomes
such as YLG) to reference year 2012 at 3% year over a
time horizon of 30 years (reflecting the time period our
prospectively followed study cohort was followed) (13).
Sensitivity analysis
We performed a sensitivity analysis for the cost/early-
stage tumour detected under both hypothetical screening
methods by varying the percentage of late-stage tumours
identified by AFP0US that would have been identified
by US-alone at an early stage from 0% (indicating that
the 2 methods had the same sensitivity) to 100% (indicat-
ing that US-alone identified all tumours in the cohort at
an early stage). The base-case analysis assumed approxi-
mately 33% difference between the 2 methods.
We also considered the impact if all persons in our
cohort had received HCC screening every 6 months as
recommended. Of the 21,226 potential screening oppor-
tunities in the cohort, only 10,931 screenings occurred
(approximately 51% of potential screenings) (Table I).
Results
To summarise key input data for our cost analysis model
(Tables I and II), the median survival among persons
with early-stage HCC tumours was 3.1 years (minimum
[min] 0.3 years; maximum [max] 14.2 years), and
for late-stage tumours was 0.2 years (min 0 years;
max 2.3 years). Of the 21 tumours that occurred in the
prospectively followed cohort, 10 (47%) might have been
identified by AFP0US at an early stage. Assuming that
approximately 33% of tumours identified at a late stage by
AFP0US were instead detected by the US-alone method
at an early stage, then 14 (67%) tumours might have been
detected at an early stage by US-alone.
Our base-case analysis indicates that US-alone alone
would have yielded more total YLG compared with
AFP0US. Undiscounted YLG in the cohort based on
median survival by US-alone was estimated at 41.4 years
compared with 29.6 years by AFP0US (Table III).
However, the undiscounted total direct cost of the screen-
ing program, without including transportation costs,
during the study period would have been $1.2 million by
US-alone compared to $528,000 by AFP0US. Discounting
at 3%/year reduced those costs to $357,000 and $814,000,
respectively. The approximate undiscounted cost/YLG with-
out including transportation costs was lower for AFP0US
($18,000) than US-alone ($39,000) (discounted approxi-
mately $13,000 and $21,000, respectively). The total cost of
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the screening program in the cohort, the cost/tumour
detected, and the cost/YLG at median/mean survival by
AFP0US remained lower than US-alone after account-
ing for travel expenditure (Table III).
Compared to the AFP0US method, the US-only
method had an incremental cost of $100,000 per each
additional YLG and $279,000 per each additional early-
stage tumour detected (discounted costs including trans-
portation costs). Excluding transportation costs reduced
this to $41,000 per additional YLG and $114,000 per
each additional early-stage tumour detected (Table III).
Sensitivity analysis
Figure 1 depicts the discounted cost per early-stage tumour
detected for the AFP0US and US-alone methods as the
percentage of late-stage tumours identified by AFP0US
that would potentially have been identified by US-alone
at an early stage increases from 0 to 100%. Because we only
varied the number of tumours detected by the US-alone
method in this analysis, the discounted cost for the
AFP0US method remained stable at $36,000/early-stage
tumour detected without accounting for travel costs and
$59,000 when including travel costs. The discounted cost
for US-alone ranged from $38,759 to $81,393/early-stage
tumour detected without including travel costs and from
$81,064 to $170,235 when including travel costs.
If all persons in our cohort had received HCC screening
every 6 months as recommended (i.e. 100% adherence),
the total direct discounted costs of the screening program
without accounting for travel expenses would have been
$556,000 by AFP0US compared with $1.6 million by
US-alone (results not shown). Assuming US-alone could
have identified all tumours in the cohort at an early stage,
full compliance with screening opportunities would have
produced a discounted cost without travel expenses of
$78,000/early-stage tumour detected.
Discussion
We compared the cost-effectiveness of HCC screening
by using the US-alone method versus AFP0US method
in AN people with CHB. Because AASLD guidelines
recommend HCC screening by US and discourage using





AFP0USc,d US-aloned AFP0USc,d US-aloned
Analysis without discounting
Total cost for cohort (Base Year 2012) $528,000 $1,203,000 $868,000 $2,517,000
No. of early-tumours detectede 10 14 10 14
Median (mean) YLG for Cohort 29.6 (42) 41.4 (58.8) 29.6 (42) 41.4 (58.8)
Cost/early-stage tumour detected $53,000 $86,000 $87,000 $180,000









Extra cost ($)/extra early-tumour detected $169,000 $412,000
Extra cost ($)/Extra YLG at Median (Mean) $57,000 ($40,000) $139,000 ($98,000)
Analysis with discountingg
Total cost for cohort (Base year 2012) $357,000 $814,000 $587,000 $1,702,000
No. of early-tumours detectede 10 14 10 14
Median (mean) YLG for Cohort 27.8 (38.1) 38.9 (53.3) 27.8 (38.1) 38.9 (53.3)
Cost/early-stage tumour detection $36,000 $58,000 $59,000 $122,000
Cost/YLG at median (mean) $13,000 ($9,400) $21,000 ($15,000) $21,000 ($15,000) $44,000 ($32,000)
Incremental cost-effectiveness ratiosf
Extra cost ($)/extra early-tumour detected $114,000 $279,000
Extra cost ($)/extra YLG at median (mean) $41,000 ($30,000) $100,000 ($73,000)
AFP, alpha-fetoprotein; HCC, hepatocellular carcinoma; US, ultrasound; YLG, years of life gained.
aIn a cohort of 839 hepatitis B virus infected AN men aged ]40 years and women aged ]50 years. bTotal costs rounded to the nearest
thousand. cAssumes patients received screening for HCC by serum AFP measurements initially and switched to ultrasound for all
subsequent screenings if AFP 10 ng/mL. dAssumes patients received screening for HCC on dates for which AFP measurements were
recorded. eEarly-tumour if single tumour 55 cm in diameter or 53 tumours 53 cm in diameter; model assumes 33% (4) of tumours
identified at a late stage by the AFP0US method were identified by the US-alone method at an early stage. fRatio(costs US-alone 
costs AFP0US)/(outcome US-alone  outcome AFP0US), where outcomes are the number of early-tumours detected or number YLG
by early detection. Treatment costs after the detection of tumour (early or late) are not included in these estimates. gDiscounted direct
costs of screening and YLG at 3%/year (reference year 2012) over a 30-year time horizon.
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AFP as an HCC screening test, we wanted to compare
AFP with the best reported sensitivity of US for detecting
HCC. Our results indicate that HCC screening by US-
alone might have detected more tumours at an early
stage but the overall cost of the screening program would
have been more than twice the AFP0US method. Despite
using sensitivity estimates for detecting HCC tumours in
our model that favoured US as the more effective test
compared with AFP, the cost/early-stage tumour detected
by the AFP0US method remained lower than the US-
alone method, even when we assumed US-alone identified
all tumours at an early stage in the sensitivity analysis.
The applicability of our study findings to other health
systems must be considered within the unique resource
and epidemiologic context of each setting. For example,
the cost of a screening program is fixed but the cost/tumour
detected is enhanced in regions with a higher incidence of
HCC because of a greater potential to detect tumours.
This concept is demonstrated by an analysis of an HCC
screening program that used both US and AFP at a
teaching hospital in Australia (14). The incidence of HCC
at the hospital was 2.7%/year and the adjusted cost/tumour
detected in 2012 US dollars was approximately $12,600.
Because HCC incidence was 10 times higher at that
teaching hospital in Australia than in the AN population,
the cost/tumour detected was 4 to 8 times lower than
either of the methods in our unadjusted model. However,
in China, which has a very high prevalence of CHB
(7.9% among adults in southeast China), annual per capita
spending on health in 2002 was $55 and half of Chinese
residents in 1 survey stated that they skipped health
services because of cost (1517). In that context, initial
screening by AFP (US$0.60/test in 1997) might be more
feasible than lifelong screening by US alone (US$1.20/test
in 1997) every 6 months (18).
The effectiveness of a screening program in detecting
HCC tumours at an early stage depends on patients’
adherence with recommended screenings. Persons in our
cohort received the recommended HCC screening only
about half of the time during the 30-year study period. By
comparison, 60% of patients at 2 gastroenterology clinics
in California with CHB had received optimal screening
for HCC over a 3-year period (19). In an HCC screening
trial among persons with CHB in China, adherence to
screening was 58% over a 5-year period (20). The reasons
for suboptimal adherence in our study cohort are unclear.
An automated system mails a letter to all AN persons in
the CHB registry reminding them to have their blood
drawn for AFP measurement, thus eliminating the need for
a provider to initiate screening. However, many patients
(especially those in rural Alaskan villages) with a normal
AFP measurement are notified of the result by mail only.
The lack of regular contact with a provider combined
with the need for lifelong semi-annual phlebotomy could
partly account for the suboptimal adherence.
Our study has several limitations. First, our cost-
effectiveness analysis did not take into account the treat-
ments costs for early- and late-stage tumours. We were
unable to account for treatment costs because the HCC
treatment algorithm is complex, and we lacked data on the
probability of receiving the various treatments and their
associated outcomes (3). However, it is likely that the US-
alone screening approach would have remained more
costly even after taking into account treatment costs
because of the longer survival of the additional patients
that would be detected at an early stage and the eligibility
of those patients for more expensive treatments such as
liver transplantation. In addition, Medicare reimburse-
ment rates might not reflect the true cost of a screening test
and it is likely that the cost of those tests might have
declined over time because of increases in availability of
the test or operators’ productivity. Although we might
Fig. 1. Sensitivity analysis: Impact of varying the percentage of
hepatocellular carcinoma tumours that were identified by
AFP0US at a late stage and potentially identified by US-alone
at an early stage in hepatitis B virus infected AN persons.*$%§’
Abbreviations: AFP, alpha-fetoprotein; US, ultrasound; ¡,
indicates base-case assumption
*Screening assumed to start for men at age ]40 years and for
women at age ]50 years.
$AFP0US assumes patients received screening for HCC by
serum AFP measurements initially and switched to ultrasound if
AFP 10 ng/mL; screening method resembles the Alaska Native
Health System hepatocellular carcinoma screening program.
%The number of additional tumours that might have been
detected at an early stage (i.e. single tumour 55 cm in diameter
or 53 tumours 53 cm in diameter) by an US-alone method is
unknown; therefore, sensitivity analysis determined the cost/early-
stage tumour detected by assuming US-alone method identified
0100% of the tumours identified by AFP0US at a late stage.
§Direct costs of screening discounted at 3%/year (reference year
2012) over a 30-year time horizon.
’Assumes 60% of patients lived in a village without ready US
access and required transportation to US facility.
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have underestimated the overall cost of the screening
program, our interpretation of the relative costs of both
methods should be unaffected because we used the same
test cost estimates for both the AFP0US and US-alone
method.
Our study also has strengths. Epidemiologic and
clinical data for our cost-effectiveness analysis model
were obtained from a large population-based cohort of
persons at high risk for HCC who were followed
prospectively for up to 30 years. As a result, our model
accounts for important real-world factors that affect the
cost-effectiveness of a screening program such as patient
non-adherence. Moreover, it is unlikely that any persons
in our cohort with HCC were missed because the Alaska
Native Medical Center is the tertiary referral centre for
all persons in our cohort and all cohort patients were
cross-referenced with the Alaska Native Tumor Registry.
Finally, our sensitivity analysis surrounding several
model assumptions enhances the generalisability of our
results. For example, our assumption regarding the
number of HCC tumours that would have been identified
at an early stage by US-alone versus AFP0US relied on
papers where the study populations were not representa-
tive of our cohort (10,21). However, our sensitivity
analysis demonstrated that AFP0US remained more
cost-effective than US-alone over a broad range of
difference in sensitivity between the 2 HCC screening
methods.
Decisions surrounding the optimal method to screen
for HCC must balance the cost-effectiveness, as presented
here, with other factors not included in this analysis,
such as the availability and quality of the screening test
(e.g. sensitivity/specificity) (22). The efficacy of AFP as a
screening tool for HCC has long been criticised for having
a lower sensitivity and specificity than imaging modalities
(23,24). But for many of patients in rural Alaska, AFP is
the only locally available option for HCC screening, and
it could potentially identify patients with CHB at high
risk for HCC who could benefit from referral for a liver
ultrasound or CT. Thus, public health officials should
evaluate the cost-effectiveness of AFP0US to increase
access to HCC screening for persons living in remote
communities without access to US.
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Appendix Table I. Demographic and clinical characteristics of the cohort participants with history of hepatitis B virus (HBV) infection
and those who developed hepatocellular carcinoma (HCC)  Alaska, 19832012.a
Participants with HBVb Participants with HCC
Characteristics N 839 N 21
Ethnic Group
Eskimo 656 (78%) 21 (100%)
Aleut 87 (10%) 0
Indian 96 (11%) 0
Urban residence 211 (25%) 5 (24%)
Patients alivec 553 (66%) 3 (14%)
Mean (median) age of patients alivec 56 (55) years 66 (73) years
Mean (median) person-years of follow-up 12 (11) years 10 (9) years
Mean (median) age at HCC diagnosis  61 (61) years
HBV Genotype
A 105 (13%) 2 (10%)
B 44 (5%) 0
C 54 (6%) 9 (43%)
D 387 (46%) 5 (24%)
F 117 (14%) 5 (24%)
H 1 (0.1%) 0
Unknown 131 (16%) 0
Cirrhosis present at HCC diagnosisd Unknown 8 (38%)
aAnalysis restricted to males aged 40 years and females aged 50 years. bIncludes patients with HBV infection who subsequently
cleared hepatitis B surface antigen. cAs of 12/31/2012. dBiopsy confirmed.
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